Subsequently, the combination of PD-L1 inhibitor (atezolizumab) and vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) proved to be the first drug with significantly better efficacy than sorafenib in more than a decade, ushering in a new era of combination therapy for HCC immunotherapy (5). The gene discussed is CD274; the disease is hepatocellular carcinoma.